Blue Owl Capital Holdings LP Buys 167,200 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Blue Owl Capital Holdings LP grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 65.5% in the third quarter, Holdings Channel.com reports. The firm owned 422,438 shares of the biopharmaceutical company’s stock after acquiring an additional 167,200 shares during the quarter. Ultragenyx Pharmaceutical makes up approximately 3.9% of Blue Owl Capital Holdings LP’s investment portfolio, making the stock its 9th biggest position. Blue Owl Capital Holdings LP’s holdings in Ultragenyx Pharmaceutical were worth $12,707,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Assetmark Inc. boosted its stake in Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,024 shares during the last quarter. Huntington National Bank increased its stake in shares of Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 205.4% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,169 shares during the last quarter. Covestor Ltd raised its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 369 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $55,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on RARE. Leerink Partners dropped their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Canaccord Genuity Group reduced their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Robert W. Baird decreased their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. HC Wainwright dropped their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Sixteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $68.29.

Ultragenyx Pharmaceutical Stock Down 1.0%

Shares of Ultragenyx Pharmaceutical stock opened at $21.25 on Friday. The firm has a market cap of $2.05 billion, a PE ratio of -3.64 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.41 and a 52 week high of $42.37. The business’s fifty day simple moving average is $23.04 and its 200-day simple moving average is $29.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The firm’s revenue for the quarter was up 25.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.39) earnings per share. As a group, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Erik Harris sold 10,539 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $240,289.20. Following the completion of the sale, the executive vice president directly owned 89,515 shares in the company, valued at $2,040,942. This trade represents a 10.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Howard Horn sold 8,409 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.70, for a total transaction of $190,884.30. Following the completion of the sale, the chief financial officer directly owned 86,669 shares in the company, valued at $1,967,386.30. This trade represents a 8.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 108,039 shares of company stock valued at $2,506,945 over the last quarter. 5.50% of the stock is owned by insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.